No impact of insulin resistance on FE-1 levels or rate of EPI in obese patients

Key clinical point: Blood specimens from patients with chronic pancreatitis (CP) yielded a panel of 6 metabolites that showed differential expression with the presence or absence of exocrine pancreatic insufficiency (EPI;

Key clinical point: Presence of insulin resistance did not change the fecal elastase-1 (FE-1) levels or the rate of exocrine pancreatic insufficiency (EPI) in patients with obesity.

Major finding: Mean FE-1 levels (430.27 ± 207.63 vs. 508.64 ± 188.77; P = .119) and the rate of EPI (FE-1 < 200 mg/g; 25.7% vs. 10.0%; P = .104) were not significantly different in patients with or without insulin resistance.

Study details: Findings are from a retrospective analysis of 65 patients with obesity (body mass index, >30 kg/m²) with (n=35) or without (n=30) insulin resistance.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Uysal BB et al. Med Sci. 2021 Aug 23. doi: 10.5455/medscience.2021.05.164.

Key clinical point: Blood specimens from patients with chronic pancreatitis (CP) yielded a panel of 6 metabolites that showed differential expression with the presence or absence of exocrine pancreatic insufficiency (EPI;

Key clinical point: Presence of insulin resistance did not change the fecal elastase-1 (FE-1) levels or the rate of exocrine pancreatic insufficiency (EPI) in patients with obesity.

Major finding: Mean FE-1 levels (430.27 ± 207.63 vs. 508.64 ± 188.77; P = .119) and the rate of EPI (FE-1 < 200 mg/g; 25.7% vs. 10.0%; P = .104) were not significantly different in patients with or without insulin resistance.

Study details: Findings are from a retrospective analysis of 65 patients with obesity (body mass index, >30 kg/m²) with (n=35) or without (n=30) insulin resistance.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Uysal BB et al. Med Sci. 2021 Aug 23. doi: 10.5455/medscience.2021.05.164.

Key clinical point: Blood specimens from patients with chronic pancreatitis (CP) yielded a panel of 6 metabolites that showed differential expression with the presence or absence of exocrine pancreatic insufficiency (EPI;

Key clinical point: Presence of insulin resistance did not change the fecal elastase-1 (FE-1) levels or the rate of exocrine pancreatic insufficiency (EPI) in patients with obesity.

Major finding: Mean FE-1 levels (430.27 ± 207.63 vs. 508.64 ± 188.77; P = .119) and the rate of EPI (FE-1 < 200 mg/g; 25.7% vs. 10.0%; P = .104) were not significantly different in patients with or without insulin resistance.

Study details: Findings are from a retrospective analysis of 65 patients with obesity (body mass index, >30 kg/m²) with (n=35) or without (n=30) insulin resistance.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Uysal BB et al. Med Sci. 2021 Aug 23. doi: 10.5455/medscience.2021.05.164.